TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06039735

Intervention type: OTHER
Intervention: Chemotherapy and/or autologous hematopoietic stem cell transplantation
Description: Didn't interfere patients' treatment plan. Patients with chemotherapy (lenalidomide,bortezomib and dexamethasone) and/or autologous hematopoietic stem cell transplantation(ASCT) which is assessed by clinical doctors and only conventional treatments were used
Study: NCT06470906

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Group
Description: The intervention is a mixture of two probiotics: 1) Lactobacillus acidophilus GLA-14 and 2) Lactobacillus rhamnosus HN001. These products will be combined into a single capsule/sachet with a dose of approximately 10\^10 colony forming units (CFUs) of GLA-14 (ATCC SD5212) and HN001 (ATCC SD5675) in a 4:1 ratio, using similar doses as recent studies using this product.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: The placebo will of be Maltodextrin, a carbohydrate, packaged similarly to the intervention and having the same weight.
Study: NCT06031883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Total intravenous anesthesia in craniotomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Total intravenous anesthesia in craniotomy
Study: NCT05234567

Intervention type: BIOLOGICAL
Intervention: Asfotase Alfa
Description: All participants will receive asfotase alfa subcutaneously per standard of care. Unless otherwise specified per the Physician's standard of care, participants aged \< 2 years are recommended for a clinic visit approximately every 3 months after Enrollment until 2 years of age, after which they should have a clinic visit approximately every 6 months. Participants should be followed for 5 years, as possible.
Study: NCT06238388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542 Injection
Description: A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.
Study: NCT06471556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylprednisolone pulses
Description: Six (6) pulses (max) are performed at a 4 weeks interval (+/- 10 days). Each pulse is a 3-days-6h-perfusions of Methylprednisolone (500mg and 120mg) 10mg/kg/day diluted in 50ml of saline under supervision of SpO2, heart rate, blood pressure /
Study: NCT06090994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huaier granule
Description: Oral administration, 10g once, 3 times a day, starting within 14 days-2 months after surgery. Please refer to the medication manual for specific usage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Oral administration, 1250mg/m\^2, twice a day (2500mg/m\^2/d),day 1-14,with one course of treatment every 3 weeks, for a total of 4-6 courses.
Study: NCT06561789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functionalized Nano ᵦ tricalcium phosphate particles
Description: The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nano ᵦ tricalcium phosphate particles
Description: The intervention is a prepared mouth wash solution for remineralization of demineralized enamel by the investigator at Nano Gate institute (Egypt,cairo,elmokatm)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sodium fluoride mouth wash
Description: The intervention is mouth wash solution for remineralization of demineralized enamel from Oral-B company
Study: NCT04742686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: 5-day, power-assisted, low- to moderate-intensity, aerobic exercise training programme. Exercise duration to progress from 10 minutes on day 1, to 30 minutes on day 5. Exercise equipment: Letto-2 (Motomed, Germany).
Study: NCT06563271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol 50 Mg/mL Solution for Injection
Description: Dexketoprofen 50 mg administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 100 MG/ML Solution for Injection
Description: Ibuprofen 100 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).~Group P: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol 10 Mg/mL Solution for Injection
Description: Paracetamol 10 mg/ml administered parenterally (intravenously in 150 cc isotonic saline over 15 minutes infusion).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: Ibuprofen and dexketoprofen will be administered intravenously (IV) by mixing them into 150 cc of isotonic saline.
Study: NCT06397560

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PRDR
Description: Proton pulsed reduced dose rate (PRDR) technique, to a dose of 54 Gy in 30 fractions (treatments) with proton radiotherapy. Treatments will occur once per day on consecutive weekdays.
Study: NCT04349475

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention Omega 3 Supplementation
Description: Participants will supplement 4g of Omega 3 fish oil daily (750DHA/250EPA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Safflower Oil
Description: Participants will consume 2.5g of a Safflower oil supplement daily
Study: NCT05670106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11
Description: single intravenous dose of approximately 150 MBq. Administered dose must not be lower than 111 MBq or higher than 259 MBq (3 - 7 mCi).
Study: NCT05599425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Healthy Living Education
Description: 24-session healthy living education program, with enhanced content about health beliefs and mechanisms of behavior change

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Healthy Living Education
Description: 24-session healthy living education program
Study: NCT05302752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic phrenic nerve stimulation
Description: The intervention consists of bilateral rapid magnetic phrenic nerve stimulation on the neck using different stimulation intensities.~On one visit, the effect of increasing chest wall stiffness and respiratory muscle work by adding incrementally small weights to the chest/abdomen will be investigated.
Study: NCT04714112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
Study: NCT05921500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium peborate
Description: Internal bleaching of discolored primary anterior teeth by using sodium peborate
Study: NCT05162235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Reality-assisted localization of solitary pulmonary nodule
Description: In this study, AR was utilized to assist in the localization of SPNs during sublobectomy lung resection in patient to assess the safety and effectiveness of the technique.
Study: NCT05972187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature and Humidity
Description: Temperature and Humidity of room changed
Study: NCT04783207

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mitopure
Description: Softgel containing 250 mg of Urolithin A (Mitopure) with excipients. 4 soft-gels to be taken daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Softgel containing only excipients. 4 soft-gels to be taken daily
Study: NCT05308147

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: First Reference product
Description: Dextrose (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Second Reference product
Description: Dextrose (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Third Reference product
Description: Dextrose (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: First Concept product
Description: Infant Formula (containing 25 grams of carbohydrates)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Second Concept product
Description: Infant Formula with new carbohydrate mixture 1 (containing 25 grams of carbohydrates)
Study: NCT06169085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leritrelvir
Description: Oral
Study: NCT06096948

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEXPOWDER-ENDOHS
Description: Standard of care ESD or EMR procedure and application of Nexpowder on the resection site to prevent delayed bleeding.
Study: NCT06293183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Participants in the intervention group will be expected to watch the training video in the mobile application installed on their phones or tablets and then regularly enter all the food and liquid amounts they consume during the day into this application. In the mobile application data entry area, visuals that will be included in the application showing the amount and types of foods consumed by the participants during the day (1 soup bowl, 1 vegetable dish plate, 1 meat dish plate, 1 water glass, 1 tea glass, tablespoon, dessert spoon, teaspoon, ladle). etc.) will choose through. The mobile application will calculate the total amount of liquid consumed by the participants in 24 hours, and will give a yellow warning when the amount of liquid consumed is 2-2.5 liters, an orange warning when it is 2.5-3 liters, and a red warning when it is 3 liters and above. This will contribute to reducing the amount of fluid intake of participants between two dialysis sessions.
Study: NCT05811676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Intravenous administration of 10 mL (1 g of tranexamic acid), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Intravenous administration of 10 mL placebo(0.9% sodium chloride), diluted in 40 ml of normal saline, over 10 minutes after umbilical-cord clamping, the routine prophylactic uterotonic administration
Study: NCT04880434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Brexucabtagene autoleucel
Description: A single infusion of brexucabtagene autoleucel (KTE-X19) anti-CD 19 CAR T cells
Study: NCT05819398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab Formulation 1
Description: Spesolimab Formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab Formulation 1
Description: Spesolimab Formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab Formulation 1
Description: Spesolimab Formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab Formulation 2
Description: Spesolimab Formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab Formulation 2
Description: Spesolimab Formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab Formulation 2
Description: Spesolimab Formulation 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab Formulation 2
Description: Spesolimab Formulation 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Spesolimab Formulation 1
Description: Placebo matching Spesolimab Formulation 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Spesolimab Formulation 2
Description: Placebo matching Spesolimab Formulation 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Spesolimab Formulation 2
Description: Placebo matching Spesolimab Formulation 2
Study: NCT05308147

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Third Concept product
Description: Infant Formula with new carbohydrate mixture 2 (containing 25 grams of carbohydrates)
Study: NCT05332444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: susceptibility-guided tailored therapy (Group A)
Description: Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: guidelines-recommended empiric therapy (Group B)
Description: bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
Study: NCT05466435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heavy Slow Resistance
Description: Heavy slow resistance exercise will be given twice a week for 12 weeks along with traditional physical therapy program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Traditional physical therapy program only will be given twice a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: Traditional physical therapy program only will be given twice a week for 12 weeks
Study: NCT04630795

Intervention type: DEVICE
Intervention: ViscoTurf insole
Description: Intervention insole will be produced as 3D printed insole with the Turf-Like patches incorporated in the areas of interest.

Intervention type: DEVICE
Intervention: Control insole
Description: Control Insole will be a standard 3D printed flat insole with NO Turf-like patches.
Study: NCT04166630

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical Electrical Stimulator
Description: Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical Electrical Stimulator
Description: Conductive electrodes will be on the skin at each end of the tested muscle(s). Each subject will have two target muscle groups tested (extensor carpi radialis longus, and tibialis anterior). Each muscle will be stimulated at three separate stimulation frequencies (2 Hz, 4 Hz, and 6Hz) over 3 minutes each, for a total of 9 minutes of stimulation per muscle. The clinical electrical stimulator will deliver mild electrical stimulations to the muscle (20-100 mA).
Study: NCT04643067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPG-818 low dose
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPG-818 mid dose
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KPG-818 high dose
Description: The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is the comparative arm.
Study: NCT05886920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D3S-002
Description: Oral
Study: NCT05710783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX-COVID/12
Description: Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX-COVID/12
Description: Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX-COVID/12
Description: Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVX-COVID/12
Description: Single dose IM administration of a Recombinant Newcastle Disease Virus Vectored Vaccine for SARS-CoV-2

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx-1-S[recombinant]
Description: Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx-1-S[recombinant]
Description: Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx-1-S[recombinant]
Description: Single dose IM administration of ChAdOx1 nCOV-19 (Astra-Zeneca) adenovirus-vectored vaccine
Study: NCT06249360

Intervention type: OTHER
Intervention: Veins with reflux
Description: This group included patients who used only recipient veins with reflux

Intervention type: OTHER
Intervention: Reflux-free recipient veins
Description: This group included patients who utilized only reflux-free recipient veins
Study: NCT06057727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit patient text messaging
Description: Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-visit patient text messaging
Description: Patients will be sent text message reminders 3 days and 24 hours prior to their scheduled primary care visit. The messages will inform the patient that a flu shot has been reserved for them at their upcoming appointment and encouraging the patient to ask their provider about receiving the vaccine.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default pended order
Description: A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default pended order
Description: A default pended order for the flu vaccine will be pended to the patient's upcoming primary care encounter and will be visible to the provider during the visit encounter. Clinical staff will have the option of signing the order or dismissing it if they deem it inappropriate for a given patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly peer comparison feedback
Description: Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly peer comparison feedback
Description: Each month, clinicians will be sent an email containing what percent of their eligible patients received the flu vaccine and how that compares to other peer clinicians in the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High risk bidirectional pre-visit text messaging
Description: High risk patients randomized to receive the high risk intensification nudge will receive a bidirectional text messaging component prior to their visit. This intervention will query the patient about common questions or concerns about receiving the flu vaccine. If the patient responds, it will provide additional educational materials based on the patient's specific concern(s).
Study: NCT05988983

Intervention type: OTHER
Intervention: Availability of OTC contraceptive pill
Description: Over the counter contraceptive pill
Study: NCT05410002

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: N-111
Description: Dietary supplement N-111

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: N-111
Description: Dietary supplement N-111

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dietary placebo
Study: NCT05754203

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Super-hyperfractionation Pulse Radiotherapy
Description: Radiotherapy design: a single dose of 0.5Gy, 16 consecutive pulses with an interval of 3 minutes (0.5Gy \* 16F), total dose DT: 8Gy; Immunotherapy: PD-1/PD-L1 monoclonal antibodies conforming to CSCO guidelines for lung cancer indications, including Carrilizumab, Tirelizumab, Teripril, Paborizumab, etc., conventional therapeutic dose, Q3W, until progression or the investigator judges that there is no longer clinical benefit or intolerable side effects.